The RESQU-SARC trial, sponsored by M.D. Anderson Cancer Center, aims to evaluate the efficacy of repeat versus single quadratus lumborum blocks in reducing opioid prescriptions post-surgery for retroperitoneal sarcoma patients. Given the increasing scrutiny on opioid prescriptions due to addiction concerns, this trial addresses a significant market need for effective pain management alternatives. The successful outcome could position liposomal bupivacaine as a preferred option in postoperative pain management, potentially influencing market dynamics and competitive positioning against existing analgesics. The collaboration with the National Cancer Institute (NCI) further enhances credibility and may facilitate broader adoption within clinical settings.